How human cells defend against certain bacterial infections
Interferon-inducible cell-autonomous immunity to cytosolic bacterial pathogens
This study looks at how our body's own cells, especially those in the gut, use a special signal from the immune system to fight off harmful bacteria, which could help us find new ways to treat infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11013922 on NIH RePORTER |
What this research studies
This research investigates how human cells, particularly epithelial cells, utilize their own defense mechanisms to protect against bacterial pathogens. It focuses on the role of interferon-gamma, a signaling molecule from immune cells, in activating genes that produce antimicrobial proteins. By studying the interactions between these proteins and bacteria, the research aims to uncover new insights into how cells can autonomously fight off infections. This could lead to better understanding and potential treatments for bacterial infections that affect the gut and other areas.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals, particularly children under 11 years old, who are susceptible to bacterial infections such as bacillary dysentery.
Not a fit: Patients with non-bacterial infections or those who do not have a history of bacterial infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the body's natural ability to fight bacterial infections.
How similar studies have performed: Previous research has shown promising results in understanding cell-autonomous immunity, but this specific approach focusing on GBP1 and its interactions with bacteria is relatively novel.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Coers, Joern — Duke University
- Study coordinator: Coers, Joern
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.